Acute GVHD is a major complication and cause of death after allogeneic hematopoietic stem-cell transplantation. Even with standard prophylaxis regimens, GVHD occurs in 34 to 51% of patients within 100 days of transplantation. New research findings are summarized in a short video. To read the full article, click the link: https://nej.md/3baWUWd | The New England Journal of Medicine

Treatments like CAR T are expected to be delivered in more outpatient clinics this year and, in some cases, at home. Advances in remote monitoring and digital health are making it possible to reduce hospital stays, lower costs and help more patients access leading-edge care. At City of Hope, CAR T therapy and stem cell transplantation are already being delivered in outpatient settings, pointing to where cancer care is headed next. Dr. Eileen Smith, the Francis & Kathleen McNamara Distinguished C